nodes	percent_of_prediction	percent_of_DWPC	metapath
Methamphetamine—SLC6A2—locus ceruleus—narcolepsy	0.0794	0.151	CbGeAlD
Methamphetamine—MAOA—locus ceruleus—narcolepsy	0.0731	0.139	CbGeAlD
Methamphetamine—SLC6A2—autonomic nervous system—narcolepsy	0.0422	0.0804	CbGeAlD
Methamphetamine—SLC18A1—brain—narcolepsy	0.0209	0.0399	CbGeAlD
Methamphetamine—SLC18A2—brainstem—narcolepsy	0.0167	0.0318	CbGeAlD
Methamphetamine—SLC18A2—forebrain—narcolepsy	0.0161	0.0307	CbGeAlD
Methamphetamine—SLC6A3—brainstem—narcolepsy	0.0126	0.0241	CbGeAlD
Methamphetamine—SLC6A3—forebrain—narcolepsy	0.0122	0.0232	CbGeAlD
Methamphetamine—SLC18A2—medulla oblongata—narcolepsy	0.0116	0.0222	CbGeAlD
Methamphetamine—SLC6A4—brainstem—narcolepsy	0.0116	0.022	CbGeAlD
Methamphetamine—SLC6A4—forebrain—narcolepsy	0.0112	0.0213	CbGeAlD
Methamphetamine—MAOB—brainstem—narcolepsy	0.011	0.021	CbGeAlD
Methamphetamine—SLC18A2—midbrain—narcolepsy	0.0106	0.0203	CbGeAlD
Methamphetamine—MAOB—forebrain—narcolepsy	0.0106	0.0202	CbGeAlD
Methamphetamine—SLC6A2—brainstem—narcolepsy	0.0102	0.0194	CbGeAlD
Methamphetamine—SLC6A2—forebrain—narcolepsy	0.00983	0.0187	CbGeAlD
Methamphetamine—MAOA—brainstem—narcolepsy	0.00938	0.0179	CbGeAlD
Methamphetamine—MAOA—forebrain—narcolepsy	0.00906	0.0173	CbGeAlD
Methamphetamine—SLC6A3—midbrain—narcolepsy	0.00805	0.0153	CbGeAlD
Methamphetamine—MAOB—medulla oblongata—narcolepsy	0.00767	0.0146	CbGeAlD
Methamphetamine—SLC6A4—midbrain—narcolepsy	0.00737	0.0141	CbGeAlD
Methamphetamine—SLC6A2—medulla oblongata—narcolepsy	0.0071	0.0135	CbGeAlD
Methamphetamine—MAOB—midbrain—narcolepsy	0.00701	0.0134	CbGeAlD
Methamphetamine—ADRA2A—forebrain—narcolepsy	0.00695	0.0132	CbGeAlD
Methamphetamine—SLC18A2—brain—narcolepsy	0.00668	0.0127	CbGeAlD
Methamphetamine—MAOA—medulla oblongata—narcolepsy	0.00654	0.0125	CbGeAlD
Methamphetamine—ADRA2B—Amine ligand-binding receptors—HRH3—narcolepsy	0.00637	0.0134	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR ligand binding—HCRTR1—narcolepsy	0.00636	0.0134	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR ligand binding—HCRTR2—narcolepsy	0.00636	0.0134	CbGpPWpGaD
Methamphetamine—ADRA2C—medulla oblongata—narcolepsy	0.00629	0.012	CbGeAlD
Methamphetamine—TAAR1—GPCR ligand binding—P2RY11—narcolepsy	0.00614	0.0129	CbGpPWpGaD
Methamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—PENK—narcolepsy	0.00611	0.0129	CbGpPWpGaD
Methamphetamine—SLC22A5—medulla oblongata—narcolepsy	0.00603	0.0115	CbGeAlD
Methamphetamine—MAOA—midbrain—narcolepsy	0.00598	0.0114	CbGeAlD
Methamphetamine—ADRA2C—Amine ligand-binding receptors—HRH3—narcolepsy	0.00595	0.0125	CbGpPWpGaD
Methamphetamine—ADRA2C—midbrain—narcolepsy	0.00575	0.011	CbGeAlD
Methamphetamine—CYP2D6—brainstem—narcolepsy	0.00558	0.0106	CbGeAlD
Methamphetamine—SLC22A5—midbrain—narcolepsy	0.00551	0.0105	CbGeAlD
Methamphetamine—CYP2D6—forebrain—narcolepsy	0.00538	0.0103	CbGeAlD
Methamphetamine—TAAR1—GPCR ligand binding—HCRT—narcolepsy	0.00522	0.011	CbGpPWpGaD
Methamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—TRH—narcolepsy	0.0052	0.0109	CbGpPWpGaD
Methamphetamine—SLC6A3—brain—narcolepsy	0.00506	0.00964	CbGeAlD
Methamphetamine—ADRA2A—medulla oblongata—narcolepsy	0.00502	0.00957	CbGeAlD
Methamphetamine—ADRA2A—Amine ligand-binding receptors—HRH3—narcolepsy	0.00484	0.0102	CbGpPWpGaD
Methamphetamine—SLC22A3—brain—narcolepsy	0.00476	0.00907	CbGeAlD
Methamphetamine—TAAR1—GPCR ligand binding—PENK—narcolepsy	0.00465	0.00979	CbGpPWpGaD
Methamphetamine—SLC6A4—brain—narcolepsy	0.00463	0.00883	CbGeAlD
Methamphetamine—ADRA2A—midbrain—narcolepsy	0.00459	0.00875	CbGeAlD
Methamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—HRH3—narcolepsy	0.00456	0.00958	CbGpPWpGaD
Methamphetamine—SLC6A4—Circadian rythm related genes—HCRTR2—narcolepsy	0.00454	0.00954	CbGpPWpGaD
Methamphetamine—SLC6A4—Circadian rythm related genes—HCRTR1—narcolepsy	0.00454	0.00954	CbGpPWpGaD
Methamphetamine—MAOB—brain—narcolepsy	0.0044	0.0084	CbGeAlD
Methamphetamine—SLC6A2—brain—narcolepsy	0.00408	0.00777	CbGeAlD
Methamphetamine—TAAR1—GPCR ligand binding—TRH—narcolepsy	0.00396	0.00832	CbGpPWpGaD
Methamphetamine—ADRA2B—Monoamine GPCRs—HTR2A—narcolepsy	0.00378	0.00795	CbGpPWpGaD
Methamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—NPS—narcolepsy	0.00378	0.00794	CbGpPWpGaD
Methamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—TAC1—narcolepsy	0.00378	0.00794	CbGpPWpGaD
Methamphetamine—MAOA—brain—narcolepsy	0.00376	0.00716	CbGeAlD
Methamphetamine—ADRA2C—brain—narcolepsy	0.00361	0.00689	CbGeAlD
Methamphetamine—TAAR1—GPCR downstream signaling—HCRTR1—narcolepsy	0.00359	0.00756	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR downstream signaling—HCRTR2—narcolepsy	0.00359	0.00756	CbGpPWpGaD
Methamphetamine—ADRA2C—Monoamine GPCRs—HTR2A—narcolepsy	0.00353	0.00743	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR downstream signaling—P2RY11—narcolepsy	0.00347	0.0073	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR ligand binding—HRH3—narcolepsy	0.00347	0.0073	CbGpPWpGaD
Methamphetamine—SLC22A5—brain—narcolepsy	0.00346	0.0066	CbGeAlD
Methamphetamine—TAAR1—Signaling by GPCR—HCRTR1—narcolepsy	0.00326	0.00686	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—HCRTR2—narcolepsy	0.00326	0.00686	CbGpPWpGaD
Methamphetamine—ADRA2B—Amine ligand-binding receptors—HTR2A—narcolepsy	0.00318	0.00668	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—P2RY11—narcolepsy	0.00315	0.00663	CbGpPWpGaD
Methamphetamine—ADRA2C—Amine ligand-binding receptors—HTR2A—narcolepsy	0.00297	0.00624	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR downstream signaling—HCRT—narcolepsy	0.00295	0.00621	CbGpPWpGaD
Methamphetamine—ADRA2A—brain—narcolepsy	0.00288	0.0055	CbGeAlD
Methamphetamine—TAAR1—GPCR ligand binding—TAC1—narcolepsy	0.00287	0.00605	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR ligand binding—NPS—narcolepsy	0.00287	0.00605	CbGpPWpGaD
Methamphetamine—ADRA2A—Monoamine GPCRs—HTR2A—narcolepsy	0.00287	0.00603	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCRs, Class A Rhodopsin-like—HCRTR2—narcolepsy	0.00268	0.00564	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCRs, Class A Rhodopsin-like—HCRTR1—narcolepsy	0.00268	0.00564	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—HCRT—narcolepsy	0.00268	0.00564	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR downstream signaling—PENK—narcolepsy	0.00263	0.00553	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCRs, Class A Rhodopsin-like—P2RY11—narcolepsy	0.00259	0.00545	CbGpPWpGaD
Methamphetamine—SLC6A4—SIDS Susceptibility Pathways—TAC1—narcolepsy	0.00251	0.00529	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCRs, Class A Rhodopsin-like—HCRTR2—narcolepsy	0.0025	0.00527	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCRs, Class A Rhodopsin-like—HCRTR1—narcolepsy	0.0025	0.00527	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCRs, Class A Rhodopsin-like—P2RY11—narcolepsy	0.00242	0.00509	CbGpPWpGaD
Methamphetamine—ADRA2A—Amine ligand-binding receptors—HTR2A—narcolepsy	0.00241	0.00507	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—PENK—narcolepsy	0.00239	0.00502	CbGpPWpGaD
Methamphetamine—SLC6A4—Monoamine Transport—TNF—narcolepsy	0.00231	0.00486	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—HCRTR1—narcolepsy	0.0023	0.00483	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—HCRTR2—narcolepsy	0.0023	0.00483	CbGpPWpGaD
Methamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—HTR2A—narcolepsy	0.00227	0.00478	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR downstream signaling—TRH—narcolepsy	0.00224	0.0047	CbGpPWpGaD
Methamphetamine—CYP2D6—brain—narcolepsy	0.00223	0.00426	CbGeAlD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—P2RY11—narcolepsy	0.00222	0.00467	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—HCRTR2—narcolepsy	0.00215	0.00451	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—HCRTR1—narcolepsy	0.00215	0.00451	CbGpPWpGaD
Methamphetamine—ADRA2B—G alpha (i) signalling events—PENK—narcolepsy	0.00211	0.00445	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—P2RY11—narcolepsy	0.00207	0.00436	CbGpPWpGaD
Methamphetamine—MAOA—SIDS Susceptibility Pathways—TAC1—narcolepsy	0.00206	0.00433	CbGpPWpGaD
Methamphetamine—SLC6A4—Circadian rythm related genes—NPS—narcolepsy	0.00205	0.00432	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCRs, Class A Rhodopsin-like—HCRTR2—narcolepsy	0.00203	0.00428	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCRs, Class A Rhodopsin-like—HCRTR1—narcolepsy	0.00203	0.00428	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—TRH—narcolepsy	0.00203	0.00427	CbGpPWpGaD
Methamphetamine—SLC6A2—Monoamine Transport—TNF—narcolepsy	0.00198	0.00418	CbGpPWpGaD
Methamphetamine—ADRA2C—G alpha (i) signalling events—PENK—narcolepsy	0.00198	0.00416	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCRs, Class A Rhodopsin-like—P2RY11—narcolepsy	0.00196	0.00413	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR downstream signaling—HRH3—narcolepsy	0.00196	0.00412	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—HCRTR2—narcolepsy	0.00193	0.00405	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—HCRTR1—narcolepsy	0.00193	0.00405	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—HCRT—narcolepsy	0.00189	0.00397	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—P2RY11—narcolepsy	0.00186	0.00392	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—HRH3—narcolepsy	0.00178	0.00375	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—HCRT—narcolepsy	0.00176	0.00371	CbGpPWpGaD
Methamphetamine—SLC6A3—Monoamine Transport—TNF—narcolepsy	0.00176	0.0037	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—HCRTR2—narcolepsy	0.00175	0.00368	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—HCRTR1—narcolepsy	0.00175	0.00368	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HCRTR2—narcolepsy	0.00174	0.00367	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HCRTR1—narcolepsy	0.00174	0.00367	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR ligand binding—HTR2A—narcolepsy	0.00173	0.00364	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—P2RY11—narcolepsy	0.00169	0.00355	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—P2RY11—narcolepsy	0.00168	0.00354	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—PENK—narcolepsy	0.00168	0.00354	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—HCRTR2—narcolepsy	0.00163	0.00344	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—HCRTR1—narcolepsy	0.00163	0.00344	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR downstream signaling—TAC1—narcolepsy	0.00162	0.00342	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR downstream signaling—NPS—narcolepsy	0.00162	0.00342	CbGpPWpGaD
Methamphetamine—ADRA2A—G alpha (i) signalling events—PENK—narcolepsy	0.0016	0.00338	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—HCRT—narcolepsy	0.00158	0.00333	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—P2RY11—narcolepsy	0.00158	0.00332	CbGpPWpGaD
Methamphetamine—ADRA2B—G alpha (i) signalling events—HRH3—narcolepsy	0.00158	0.00332	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—PENK—narcolepsy	0.00157	0.0033	CbGpPWpGaD
Methamphetamine—SLC6A4—SIDS Susceptibility Pathways—HTR2A—narcolepsy	0.00151	0.00318	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—NPS—narcolepsy	0.00148	0.0031	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—TAC1—narcolepsy	0.00148	0.0031	CbGpPWpGaD
Methamphetamine—ADRA2C—G alpha (i) signalling events—HRH3—narcolepsy	0.00147	0.0031	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCRs, Class A Rhodopsin-like—HRH3—narcolepsy	0.00146	0.00308	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—HCRT—narcolepsy	0.00144	0.00302	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HCRT—narcolepsy	0.00143	0.00301	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—TRH—narcolepsy	0.00143	0.00301	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—PENK—narcolepsy	0.00141	0.00297	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCRs, Class A Rhodopsin-like—HRH3—narcolepsy	0.00137	0.00288	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—HCRT—narcolepsy	0.00134	0.00282	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—TRH—narcolepsy	0.00134	0.00281	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—HCRTR2—narcolepsy	0.00133	0.00279	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—HCRTR1—narcolepsy	0.00133	0.00279	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—CHKB—narcolepsy	0.0013	0.00274	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—P2RY11—narcolepsy	0.00128	0.0027	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—PENK—narcolepsy	0.00128	0.00269	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—PENK—narcolepsy	0.00128	0.00268	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—HRH3—narcolepsy	0.00125	0.00264	CbGpPWpGaD
Methamphetamine—MAOA—SIDS Susceptibility Pathways—HTR2A—narcolepsy	0.00124	0.00261	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—TRH—narcolepsy	0.0012	0.00252	CbGpPWpGaD
Methamphetamine—ADRA2A—G alpha (i) signalling events—HRH3—narcolepsy	0.0012	0.00252	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—PENK—narcolepsy	0.0012	0.00252	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—HRH3—narcolepsy	0.00117	0.00246	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCRs, Class A Rhodopsin-like—HRH3—narcolepsy	0.00111	0.00234	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—CHKB—narcolepsy	0.0011	0.00232	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—HCRT—narcolepsy	0.00109	0.00229	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—TRH—narcolepsy	0.00109	0.00229	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—TRH—narcolepsy	0.00108	0.00228	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—HRH3—narcolepsy	0.00105	0.00221	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—NPS—narcolepsy	0.00104	0.00219	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—TAC1—narcolepsy	0.00104	0.00219	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—TRH—narcolepsy	0.00102	0.00214	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—HCRTR2—narcolepsy	0.000989	0.00208	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—HCRTR1—narcolepsy	0.000989	0.00208	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR downstream signaling—HTR2A—narcolepsy	0.000977	0.00206	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—PENK—narcolepsy	0.000971	0.00204	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—NPS—narcolepsy	0.00097	0.00204	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—TAC1—narcolepsy	0.00097	0.00204	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—P2RY11—narcolepsy	0.000955	0.00201	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—HRH3—narcolepsy	0.000955	0.00201	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HRH3—narcolepsy	0.000951	0.002	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—HCRTR1—narcolepsy	0.000923	0.00194	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—HCRTR2—narcolepsy	0.000923	0.00194	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—HCRTR2—narcolepsy	0.000898	0.00189	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—HCRTR1—narcolepsy	0.000898	0.00189	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—P2RY11—narcolepsy	0.000892	0.00188	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—HRH3—narcolepsy	0.000892	0.00188	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—HTR2A—narcolepsy	0.000888	0.00187	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—CPT1B—narcolepsy	0.000886	0.00186	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—TAC1—narcolepsy	0.000872	0.00183	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—NPS—narcolepsy	0.000872	0.00183	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—P2RY11—narcolepsy	0.000867	0.00182	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—HCRTR1—narcolepsy	0.000839	0.00176	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—HCRTR2—narcolepsy	0.000839	0.00176	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—TRH—narcolepsy	0.000826	0.00174	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—CHKB—narcolepsy	0.000818	0.00172	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—HCRT—narcolepsy	0.000812	0.00171	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—P2RY11—narcolepsy	0.00081	0.0017	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—NPS—narcolepsy	0.000791	0.00166	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—TAC1—narcolepsy	0.000791	0.00166	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—NPS—narcolepsy	0.000788	0.00166	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—TAC1—narcolepsy	0.000788	0.00166	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—HCRT—narcolepsy	0.000758	0.0016	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—HCRTR2—narcolepsy	0.00075	0.00158	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—HCRTR1—narcolepsy	0.00075	0.00158	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—CPT1B—narcolepsy	0.00075	0.00158	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—TAC1—narcolepsy	0.000739	0.00155	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—NPS—narcolepsy	0.000739	0.00155	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—HCRT—narcolepsy	0.000737	0.00155	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCRs, Class A Rhodopsin-like—HTR2A—narcolepsy	0.000729	0.00153	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—P2RY11—narcolepsy	0.000724	0.00152	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—HRH3—narcolepsy	0.000724	0.00152	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—PENK—narcolepsy	0.000724	0.00152	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—HCRT—narcolepsy	0.000689	0.00145	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCRs, Class A Rhodopsin-like—HTR2A—narcolepsy	0.000681	0.00143	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—HCRTR2—narcolepsy	0.000681	0.00143	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—HCRTR1—narcolepsy	0.000681	0.00143	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—PENK—narcolepsy	0.000676	0.00142	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—CHKB—narcolepsy	0.000673	0.00142	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—P2RY11—narcolepsy	0.000658	0.00138	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—PENK—narcolepsy	0.000657	0.00138	CbGpPWpGaD
Methamphetamine—SLC6A4—SIDS Susceptibility Pathways—TNF—narcolepsy	0.00065	0.00137	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—HTR2A—narcolepsy	0.000625	0.00131	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—HCRT—narcolepsy	0.000616	0.0013	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—TRH—narcolepsy	0.000615	0.00129	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—PENK—narcolepsy	0.000614	0.00129	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—TAC1—narcolepsy	0.0006	0.00126	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—NPS—narcolepsy	0.0006	0.00126	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—narcolepsy	0.000584	0.00123	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—TRH—narcolepsy	0.000575	0.00121	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—HCRT—narcolepsy	0.000559	0.00118	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—TRH—narcolepsy	0.000559	0.00118	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—CPT1B—narcolepsy	0.000556	0.00117	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR2A—narcolepsy	0.000553	0.00116	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—PENK—narcolepsy	0.000549	0.00115	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—CHKB—narcolepsy	0.000547	0.00115	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—HRH3—narcolepsy	0.00054	0.00113	CbGpPWpGaD
Methamphetamine—MAOA—SIDS Susceptibility Pathways—TNF—narcolepsy	0.000533	0.00112	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—HCRTR2—narcolepsy	0.00053	0.00112	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—HCRTR1—narcolepsy	0.00053	0.00112	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—HTR2A—narcolepsy	0.000524	0.0011	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—TRH—narcolepsy	0.000522	0.0011	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—P2RY11—narcolepsy	0.000512	0.00108	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—HRH3—narcolepsy	0.000504	0.00106	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—PENK—narcolepsy	0.000499	0.00105	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—HCRTR2—narcolepsy	0.000495	0.00104	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—HCRTR1—narcolepsy	0.000495	0.00104	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—HRH3—narcolepsy	0.00049	0.00103	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—P2RY11—narcolepsy	0.000478	0.00101	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—HTR2A—narcolepsy	0.000476	0.001	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—narcolepsy	0.000474	0.000997	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—TRH—narcolepsy	0.000467	0.000982	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—HRH3—narcolepsy	0.000458	0.000963	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—CPT1B—narcolepsy	0.000457	0.000962	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—NPS—narcolepsy	0.000447	0.00094	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—TAC1—narcolepsy	0.000447	0.00094	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—HTR2A—narcolepsy	0.000445	0.000935	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—HCRT—narcolepsy	0.000436	0.000916	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—TRH—narcolepsy	0.000424	0.000892	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—TAC1—narcolepsy	0.000418	0.000878	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—NPS—narcolepsy	0.000418	0.000878	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—HRH3—narcolepsy	0.000409	0.000861	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—HCRT—narcolepsy	0.000407	0.000856	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—TAC1—narcolepsy	0.000406	0.000854	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—NPS—narcolepsy	0.000406	0.000854	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—HCRTR1—narcolepsy	0.000402	0.000846	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—HCRTR2—narcolepsy	0.000402	0.000846	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—P2RY11—narcolepsy	0.000389	0.000817	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PENK—narcolepsy	0.000388	0.000817	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—TAC1—narcolepsy	0.000379	0.000798	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—NPS—narcolepsy	0.000379	0.000798	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—HRH3—narcolepsy	0.000372	0.000782	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—CPT1B—narcolepsy	0.000372	0.000782	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PENK—narcolepsy	0.000363	0.000763	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—HTR2A—narcolepsy	0.000361	0.00076	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CHKB—narcolepsy	0.000356	0.000749	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—TAC1—narcolepsy	0.000339	0.000714	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—NPS—narcolepsy	0.000339	0.000714	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—HCRT—narcolepsy	0.00033	0.000695	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—TRH—narcolepsy	0.00033	0.000694	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TRH—narcolepsy	0.000308	0.000649	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—TAC1—narcolepsy	0.000308	0.000648	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—NPS—narcolepsy	0.000308	0.000648	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PENK—narcolepsy	0.000295	0.00062	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—HRH3—narcolepsy	0.000289	0.000609	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—HRH3—narcolepsy	0.00027	0.000569	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—HTR2A—narcolepsy	0.000269	0.000566	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—HTR2A—narcolepsy	0.000251	0.000528	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TRH—narcolepsy	0.00025	0.000527	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—HTR2A—narcolepsy	0.000244	0.000514	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CPT1B—narcolepsy	0.000242	0.000509	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—NPS—narcolepsy	0.00024	0.000504	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—TAC1—narcolepsy	0.00024	0.000504	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—HTR2A—narcolepsy	0.000228	0.00048	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—NPS—narcolepsy	0.000224	0.000471	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TAC1—narcolepsy	0.000224	0.000471	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—HRH3—narcolepsy	0.00022	0.000462	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—HTR2A—narcolepsy	0.000204	0.000429	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—HTR2A—narcolepsy	0.000185	0.00039	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—NPS—narcolepsy	0.000182	0.000383	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TAC1—narcolepsy	0.000182	0.000383	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—HTR2A—narcolepsy	0.000144	0.000303	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—HTR2A—narcolepsy	0.000135	0.000283	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—HTR2A—narcolepsy	0.000109	0.00023	CbGpPWpGaD
